Print

Cancer Research Consortium of West Michigan

All Open Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Brain/CNS

Cancer Type: MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS
Research Base: Alliance
Protocol: Alliance A071401

PHASE II TRIAL OF SMO/AKT/NF2 INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS

Cancer Type: High-Grade Glioma
Research Base: COG
Protocol: COG ACNS1721

COG-ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations 

Patients must be ≥ 3 years and ≤ 25 years of age at the time of enrollment on Step 0.

Patients >21 years must be IDH mutant.

Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.

Cancer Type: Codeleted Anaplastic Glioma
Research Base: CTSU
Protocol: N0577

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Cancer Type: CRANIOPHARYNGIOMAS
Research Base: Alliance
Protocol: Alliance A071601

A071601 - PHASE II TRIAL OF BRAF/MEK INHIBITORS IN PAPILLARY CRANIOPHARYNGIOMAS

Cancer Type: MENINGIOMA
Research Base: NRG
Protocol: NRG BN003

PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY RESECTED GRADE II MENINGIOMA

Cancer Type: Medulloblastoma
Research Base: COG
Protocol: COG ACNS1442

COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be greater than or equal to 3 years and less than 22 years at the time of planned enrollment on ACNS1422.

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Breast

Cancer Type: METASTATIC BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1703

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Cancer Type: Low Risk DCIS
Research Base: AFT
Protocol: AFT-25 COMET

COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL

Cancer Type: Newly Oligometastatic Breast Cancer
Research Base: NRG
Protocol: NRG BR002

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Cancer Type: HER2-NEGATIVE METASTATIC BREAST CANCER
Research Base: Alliance
Protocol: Alliance A171601

A PHASE II TRIAL ASSESSING THE TOLERABILITY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER

Cancer Type: ABC Companion
Research Base: Alliance
Protocol: Alliance A211601
EVALUATION OF MAMMOGRAPHIC BREAST DENSITY EFFECT OF ASPIRIN:
A COMPANION STUDY TO ALLIANCE STUDY A011502
Cancer Type: Metastatic Breast Cancer
Research Base: NRG
Protocol: NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Cancer Type: LOW RISK NODE POSITIVE BREAST CANCER
Research Base: NRG
Protocol: CCTG MA.39 Adjuvant

TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER

Cancer Type: Triple-Negative Invasive Breast Cancer
Research Base: NRG
Protocol: NRG BR003 Adjuvant

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Cancer Type: Triple-Negative Basal-Like Breast Cancer
Research Base: ECOG-ACRIN
Protocol: EA1131 Adjuvant

ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy

Cancer Type: Triple(-); ypT1or ypN(+)
Research Base: SWOG
Protocol: SWOG S1418 Adjuvant

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Cancer Type: RT for (+)Node?Neo Chemo f/b surg?(-)Node
Research Base: NRG
Protocol: NSABP B-51 Adjuvant

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. 

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011202 Adjuvant

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A221505 Adjuvant

RT CHARM: PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION

Cancer Type: Metastatic Breast Cancer
Research Base: AFT
Protocol: AFT-38 PATINA

AFT-38 PATINA:A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011104 CC Breast MRI

A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401 CC Weight loss

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502 CC ASA

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Cancer Type: BREAST OR GYNECOLOGIC CANCER
Research Base: NRG
Protocol: NRG CC004 CC-Sexual Desire

PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER

Cancer Type: METASTATIC HER-2+ BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1501 CC cardiac tox

S1501:  PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 16070 CC nausea

TREATMENT OF REFRACTORY NAUSEA

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116 CC cog impair

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Control

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116 CC cog impair

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Type: Cognitive Impairment in Colorectal Cancer
Research Base: URCC
Protocol: URCC 16092

Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502 CC ASA

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

Cancer Type: Evidence-Based Supportive Care
Research Base: COG
Protocol: COG ACCL15N1CD
 

COG ACCL15N1CD: Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401 CC Weight loss

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: Tissue Procurement
Research Base: NCI
Protocol: PDM 9846

PDM 9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Cancer Type: Cancer Care deliver
Research Base: SWOG
Protocol: SWOG S1415CD

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia –Trial Assessing CSF Prescribing Effectiveness and Risk (“TrACER”)”

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Cancer Type: Young Adult Survivors
Research Base: Wake Forest
Protocol: WF 10217

Work Ability in Young Adult Survivors (WAYS)

Cancer Type: BREAST OR GYNECOLOGIC CANCER
Research Base: NRG
Protocol: NRG CC004 CC-Sexual Desire

PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER

Cancer Type: Lung Cancer
Research Base: Wake Forest
Protocol: WF- 20817CD

Implementation of Smoking Cessation Services (OaSiS)

Cancer Type: Lung Cancer
Research Base: Alliance
Protocol: Alliance A221504

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)

Cancer Type: METASTATIC HER-2+ BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1501 CC cardiac tox

S1501:  PROSPECTIVE EVALUATION OF CARVEDILOL IN PREVENTION OF CARDIAC TOXICITY IN PATIENTS WITH METASTATIC HER-2+ BREAST CANCER, PHASE III

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011202 Adjuvant

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A221505 Adjuvant

RT CHARM: PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION

Cancer Type: Cancer Control
Research Base: URCC
Protocol: URCC 16070 CC nausea

TREATMENT OF REFRACTORY NAUSEA

Cancer Type: Screening
Research Base: ECOG-ACRIN
Protocol: EA1151 (TMIST)

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Cancer Type: Colon or Rectal Cancer
Research Base: ECOG-ACRIN
Protocol: EAQ162CD

EAQ162CD Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent

Cancer Type: METASTATIC BREAST CANCER
Research Base: SWOG
Protocol: SWOG S1703

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Cancer Type: Cancer Control - Nausea
Research Base: Alliance
Protocol: Alliance A221602

OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Cancer Type: ABC Companion
Research Base: Alliance
Protocol: Alliance A211601
EVALUATION OF MAMMOGRAPHIC BREAST DENSITY EFFECT OF ASPIRIN:
A COMPANION STUDY TO ALLIANCE STUDY A011502
Cancer Type: CCDR
Research Base: Alliance
Protocol: Alliance A231601CD

Improving surgical care and outcomes in older cancer patients through implementation of an efficient pre-surgical toolkit (OPTI-surg)

Cancer Type: Cancer Control
Research Base: Wake Forest
Protocol: WF 1801

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97415

WF 97415:  Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG ACCL16N1CD
 

COG-ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Cancer Type: Multiple Cancer control
Research Base: SWOG
Protocol: SWOG S1714

A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO DEVELOP A PREDICTIVE MODEL OF TAXANE-INDUCED PERIPHERAL NEUROPATHY IN CANCER PATIENTS

Cancer Type: CCDR
Research Base: Alliance
Protocol: Alliance A231602CD

Protocol Alliance A231602CD: Assessing Financial Difficulty in Patients with Blood Cancers

Cancer Type: Cancer Control- stomatitis
Research Base: Alliance
Protocol: Alliance A221701

Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches

Cancer Type: Cancer-Related Fatigue
Research Base: URCC
Protocol: URCC 18007

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Cancer Type: peripheral neuropathy in African American women
Research Base: ECOG-ACRIN
Protocol: EAZ171

Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women

Cancer Type: Prostate Cancer
Research Base: Wake Forest
Protocol: WF - 1802

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Cancer Type: Untreated Solid Tumors
Research Base: ACCRU
Protocol: ACCRU 2018-01

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Cancer Type: Untreated Hematologic Malignancies
Research Base: ACCRU
Protocol: ACCRU 2018-02

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Hematologic Malignancies

Cancer Type: Untreated Melanoma Study
Research Base: ACCRU
Protocol: ACCRU 2018-03
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Melanoma Study
Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Gastrointestinal

Cancer Type: Newly Diagnosed, Advanced Biliary Tract Cancers
Research Base: SWOG
Protocol: SWOG S1815

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Cancer Type: High Risk Anal Cancer
Research Base: ECOG-ACRIN
Protocol: EA2165

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Cancer Type: Colorectal Cancer
Research Base: NSABP-F
Protocol: NSABP FC-11
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type)
Metastatic Colorectal Cancer Based on
HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Cancer Type: Colon Cancer
Research Base: Alliance
Protocol: Alliance A021502
RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR
(ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
Cancer Type: Colorectal Cancer
Research Base: NRG
Protocol: NRG GI004

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Cancer Type: PHITT
Research Base: COG
Protocol: COG AHEP1531

COG-AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Age: Patients must be ≤ 30 years of age at the time of diagnosis

Cancer Type: Gastroenteropancreatic Neuroendocrine
Research Base: ECOG-ACRIN
Protocol: EA2142

EA2142: Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas 

Cancer Type: Colorectal
Research Base: SWOG
Protocol: SWOG S0820

SWOG S0820: A Double Blind Placebo-Controlled Trial. Eflornithine vs Sulindac vs Elfornithine + Sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers. Stage 0-III Colon Cancer, Phase III. 

Genitourinary

Cancer Type: Papillary Renal Carcinoma
Research Base: SWOG
Protocol: SWOG S1500

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Cancer Type: ADVANCED UROTHELIAL CARCINOMA
Research Base: Alliance
Protocol: Alliance A031501

PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION

Cancer Type: Prostate
Research Base: NRG
Protocol: NRG GU002

PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL

Cancer Type: Prostate Cancer
Research Base: NRG
Protocol: NRG GU005

PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER

Cancer Type: Prostate Cancer
Research Base: NRG
Protocol: NRG GU006

A PHASE II, DOUBLE-BLINDED, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCER

Cancer Type: Prostate
Research Base: ECOG-ACRIN
Protocol: EA8153
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following
Docetaxel: the CHAARTED2 Trial
Cancer Type: Metastatic Prostate Cancer
Research Base: SWOG
Protocol: SWOG S1802

 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.

Cancer Type: Bladder Cancer
Research Base: SWOG
Protocol: SWOG S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

Cancer Type: Germ Cell Tumor
Research Base: Alliance
Protocol: Alliance A031102

Alliance A031102: GERM CELL TUMORS/Relapsed or Refractory; Male Only; Comparing Conventional-Dose Chemotherapy Using paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by high-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment. Phase III Trial. 

Cancer Type: Renal-Biology
Research Base: COG
Protocol: COG AREN03B2

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis. TEMPORARY CLOSURE

Germ Cell

Cancer Type: Germ Cell
Research Base: COG
Protocol: COG AGCT1532

COG-AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell 

Age ≥ 11 years and ≤ 45 years on the date of randomization

Cancer Type: Germ Cell
Research Base: COG
Protocol: COG AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 years of age at enrollment.
  2. Standard Risk 1
    Patient must be < 11 years of age at enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 years of age at enrollment.

Gynecologic

Cancer Type: BREAST OR GYNECOLOGIC CANCER
Research Base: NRG
Protocol: NRG CC004 CC-Sexual Desire

PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER

Cancer Type: Advanced Gynecologic
Research Base: NRG
Protocol: NRG GY007

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Cancer Type: Platinum Resistant Ovarian Cancer
Research Base: NRG
Protocol: NRG GY009

A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Cancer Type: Cervical Carcinoma
Research Base: NRG
Protocol: RTOG 0724
 

RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-stage Cervical Carcinoma Following Radical Hysterectomy - 

Cancer Type: Stage I/IIA Cervical Cancer
Research Base: NRG
Protocol: GOG 0263
 

GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy; 

Cancer Type: GYN-newly diagnosed, bulky stage
Research Base: NRG
Protocol: NRG GY006

NRG GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer. 

Cancer Type: GYN-Platinum Resistant
Research Base: NRG
Protocol: NRG GY005

NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). 

Head and Neck

Cancer Type: Head and Neck
Research Base: ECOG-ACRIN
Protocol: EA3132

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck

Cancer Type: HPV Positive OPCA
Research Base: ECOG-ACRIN
Protocol: EA3161
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
 
Cancer Type: Head and Neck
Research Base: Wake Forest
Protocol: WF 97115

WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer. 

Leukemia

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL15P1

COG AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants less than 1 year of age on the date of diagnosis are eligible; infants must be >36 weeks gestational age at the time of enrollment.

Cancer Type: Ph+ ALL
Research Base: COG
Protocol: COG AALL1631

COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone

Age:  > 1 year and < 21 years at ALL diagnosis

Cancer Type: ACUTE MYELOID LEUKEMIA
Research Base: Alliance
Protocol: Alliance A041701

A RANDOMIZED PHASE II/III STUDY OF CONVENTIONAL CHEMOTHERAPY +/- UPROLESELAN (GMI- 1271) IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA RECEIVING INTENSIVE INDUCTION CHEMOTHERAPY

Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Research Base: Alliance
Protocol: Alliance A041501

A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG ACCL16N1CD
 

COG-ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

Cancer Type: Chronic Myeloid Leukemia (CML)
Research Base: SWOG
Protocol: SWOG S1712

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

Cancer Type: Relapsed Refractory CD22 B-ALL
Research Base: COG
Protocol: COG AALL1621

COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) TEMPORARY CLOSURE

Patients must be ≥1 year and < 22 years of age at the time of enrollment.

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL1521

COG-AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia 

Age ≥ 1 year and ≤ 21 years at time of leukemia diagnosis.

Cancer Type: Chronic Lymphocytic Leukemia (CLL)
Research Base: Alliance
Protocol: Alliance A041702

 “A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)” 

Cancer Type: B-ALL, B-LLy
Research Base: COG
Protocol: COG AALL1731

COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 days and < 10 years of age (B-ALL patients without DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS) 


 
Cancer Type: Leukemia
Research Base: ECOG-ACRIN
Protocol: E1910

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adult;

Cancer Type: Myelodysplastic Syndromes
Research Base: ECOG-ACRIN
Protocol: NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: AML
Research Base: COG
Protocol: COG AAML1531

COG-AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS) 

Lung

Cancer Type: Lung Cancer
Research Base: Wake Forest
Protocol: WF- 20817CD

Implementation of Smoking Cessation Services (OaSiS)

Cancer Type: Lung Cancer
Research Base: Alliance
Protocol: Alliance A221504

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)

Cancer Type: Advanced NSCLC
Research Base: ECOG-ACRIN
Protocol: EA5162

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Cancer Type: Non-Small Cell Lung Cancer (NSCLC)
Research Base: ECOG-ACRIN
Protocol: EA5163

A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Cancer Type: NSCLC
Research Base: SWOG
Protocol: LUNG MAP

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Cancer Type: NSCLC
Research Base: SWOG
Protocol: SWOG S1900A

A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (Lung-MAP SUB-STUDY)

Cancer Type: Recurrent Non-Small Cell Lung Cancer
Research Base: SWOG
Protocol: SWOG S1800A

A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Cancer Type: Limited Stage Small Cell Lung Cancer
Research Base: NRG
Protocol: NRG LU005

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Cancer Type: Lung Cancer
Research Base: SWOG
Protocol: SWOG S1400F

A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)

Cancer Type: METASTATIC NON-SMALL CELL LUNG CANCER
Research Base: NRG
Protocol: NRG LU002

MAINTENANCE SYSTEMIC THERAPY VERSUS CONSOLIDATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) PLUS MAINTENANCE SYSTEMIC THERAPY FOR LIMITED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE II/III TRIAL

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A151216

Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Cancer Type: Non-Small Cell Lung
Research Base: CTSU
Protocol: ECOG E4512

ECOG E4512: Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib/Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Cancer Type: Non-Small Cell Lung
Research Base: Alliance
Protocol: Alliance A081105

Alliance A081105: Randomized Double Blind study of Erlotinib/Placebo in patients with completely resected epidermal growth factor recepter (EGFR) mutant non-small cell lung cancer (NSCLC)

Cancer Type: SCLC
Research Base: NRG
Protocol: NRG CC003

NRG CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Cancer Type: Limited Small Cell Lung Cancer
Research Base: Alliance
Protocol: CALGB 30610
 

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide

Lymphoma

Cancer Type: Lymphoma
Research Base: Alliance
Protocol: Alliance A051301

A RANDOMIZED DOUBLE-BLIND PHASE III STUDY OF IBRUTINIB DURING AND FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS PLACEBO IN PATIENTSWITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA OF THE ACTIVATED B-CELL SUBTYPE

Cancer Type: FOLLICULAR LYMPHOMA
Research Base: SWOG
Protocol: SWOG S1608

RANDOMIZED PHASE II TRIAL IN EARLY RELAPSING OR REFRACTORY FOLLICULAR LYMPHOMA

Cancer Type: ALCL
Research Base: COG
Protocol: COG ANHL12P1

COG ANHL12P1: A Randomized Phase 2 Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL). TEMPORARY CLOSURE

Patient must be < 22 years of age.

Melanoma

Cancer Type: ADVANCED MELANOMA
Research Base: SWOG
Protocol: SWOG S1616

A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT

Cancer Type: Melanoma
Research Base: SWOG
Protocol: SWOG S1801

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

Cancer Type: Melanoma-unresectable
Research Base: ECOG-ACRIN
Protocol: ECOG EA6141

ECOG EA6141: STAGE III/IV/Unresectable Melanoma; Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab; Phase II/III Trial. 

Cancer Type: Melanoma
Research Base: ECOG-ACRIN
Protocol: ECOG EA6134

ECOG EA6134 - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma; 

Multisite

Cancer Type: Multisite
Research Base: ASCO
Protocol: TAPUR

TAPUR - Targeted Agent and Profiling Utilization Registry Study

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1K

EAY131 - Z1K Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1K: EAY131-Z1K: Ipatasertib in Patients with Tumors with AKT Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH protocol Z1L

Molecular Analysis for Therapy Choice MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase 2 Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

Cancer Type: Rare Tumors
Research Base: SWOG
Protocol: SWOG S1609 DART

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors 

Cancer Type: Multisite - Screening
Research Base: NCI
Protocol: DCP-001
 

DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Cancer Type: Tissue Procurement
Research Base: NCI
Protocol: PDM 9846

PDM 9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH
EAY131 - 'MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas; Molecular Analysis for Therapy Choice    'MATCH'
Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol A

MATCH - Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol C2

MATCH Subprotocol-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol E

MATCH - Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR.

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol J

Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol K2
 

Phase 2 Study of JNJ-42756493 (Erdafitinib)in Patients with Tumors with FGFR Mutations or Fusions.

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol L

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol M

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol T

MATCH Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol V

MATCH - Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor). 

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1E

Testing LOXO-101 as potentially targeted treatment in cancers with NTRK genetic changes

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1C

Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH protocol Z1F
 

Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1G
 

Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Cancer Type: Molecular
Research Base: ECOG-ACRIN
Protocol: EAY131 - MATCH Protocol Z1H
 

Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

Cancer Type: Germ Cell
Research Base: COG
Protocol: COG AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 years of age at enrollment.
  2. Standard Risk 1
    Patient must be < 11 years of age at enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 years of age at enrollment.
Cancer Type: All patients
Research Base: COG
Protocol: COG APEC14B1

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Cancer Type: Multisite Long Term Follow-up
Research Base: COG
Protocol: COG ALTE05N1

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Myeloma

Cancer Type: Myeloma
Research Base: Alliance
Protocol: Alliance A061202

A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib VS. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma relapsing on lenalidomide as part of first line therapy

Neuroblastoma

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Cancer Type: NBL
Research Base: COG
Protocol: COG ANBL1232

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma 

TEMPORARY CLOSURE to Group C as of October 1, 2019. Enrollment to Groups A1 and B remain open.

Cancer Type: High-Risk Neuroblastoma
Research Base: COG
Protocol: COG ANBL1531

COG ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Age - Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis.

Rare

Cancer Type: Locoregionally Advanced Head and Neck Cancer
Research Base: NRG
Protocol: NRG HN004
 

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Cancer Type: Merkel Cell Carcinoma
Research Base: Alliance
Protocol: Alliance A091605
 

Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone vs anti-PD1 antibody plus SBRT  in advanced Merkel Cell Carcinoma

Cancer Type: Merkel Cell Carcinoma
Research Base: ECOG-ACRIN
Protocol: EA6174
 

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Cancer Type: Previously Treated AL Amyloidosis
Research Base: SWOG
Protocol: SWOG S1702
 

 A Phase II Study of Isatuximab  for Previously Treated AL Amyloidosis

Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma
Research Base: ACCRU
Protocol: EA3163
 

 Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Cancer Type: advanced neuroendocrine tumors
Research Base: Alliance
Protocol: Alliance A021602
 
Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus
(CABINET)
Cancer Type: Thymic Carcinoma
Research Base: SWOG
Protocol: SWOG S1701
 

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Cancer Type: Inflammatory Breast Cancer
Research Base: SWOG
Protocol: SWOG S1706
 

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Cancer Type: Nasopharyngeal Carcinoma
Research Base: NRG
Protocol: NRG HN001
 

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Cancer Type: rare genitourinary tumors
Research Base: Alliance
Protocol: Alliance A031702
 

Phase II study of cabozantinib in combination with nivolumab and ipilimumab in rare genitourinary tumors

Cancer Type: ALK Positive Non Squamous NSCLC
Research Base: NRG
Protocol: NRG LU003
 

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

Cancer Type: Smoldering Myeloma
Research Base: ECOG-ACRIN
Protocol: EAA173
 

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) 

Cancer Type: Carcinoma of the Skin
Research Base: Alliance
Protocol: Alliance A091802
 

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin 

Sarcoma

Cancer Type: IR Rhabdomyosarcoma
Research Base: COG
Protocol: COG ARST1431

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) 

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment.